Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-19-014714
Filing Date
2019-09-30
Accepted
2019-09-30 06:06:17
Documents
53
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 form10-k.htm 10-K 1103970
2 ex31-1.htm EX-31.1 22257
3 ex31-2.htm EX-31.2 21337
4 ex32-1.htm EX-32.1 7300
5 ex32-2.htm EX-32.2 7671
6 logo_001.jpg GRAPHIC 8677
  Complete submission text file 0001493152-19-014714.txt   3643592

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE FILE nxen-20190630.xml EX-101.INS 392622
8 XBRL SCHEMA FILE nxen-20190630.xsd EX-101.SCH 46124
9 XBRL CALCULATION FILE nxen-20190630_cal.xml EX-101.CAL 34133
10 XBRL DEFINITION FILE nxen-20190630_def.xml EX-101.DEF 153348
11 XBRL LABEL FILE nxen-20190630_lab.xml EX-101.LAB 314072
12 XBRL PRESENTATION FILE nxen-20190630_pre.xml EX-101.PRE 220988
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-K | Act: 34 | File No.: 000-55320 | Film No.: 191123952
SIC: 2834 Pharmaceutical Preparations